Literature DB >> 7566976

Resistance to Fas-mediated apoptosis in human hepatoma cells.

G Natoli1, A Ianni, A Costanzo, G De Petrillo, I Ilari, P Chirillo, C Balsano, M Levrero.   

Abstract

CTLs- and lymphokine-induced apoptosis of infected hepatocytes during the course of chronic viral hepatitis is thought to be important for both disease termination and prevention of hepatocellular transformation. We therefore studied apoptosis induced by Fas (APO-1 or CD95)-a widely expressed cell surface receptor whose ligand is involved in lymphocyte cytotoxicity-in a set of human hepatoma cell lines. As normal hepatocytes, all of the human hepatoma cell lines tested do express detectable amounts of Fas on their surface. Nevertheless, only PLC/PRF/5 cells undergo apoptosis following treatment with anti-Fas. Systematic cloning and sequence analysis of the Fas cDNA did not show mutations in the Fas gene in any of the cells lines tested. However, due to alternative splicing, 5 to 10% of the Fas cDNAs are deleted of 63 internal nucleotides corresponding to the transmembrane domain, thus encoding for a soluble and secreted form of Fas (Fas delta TM), potentially able to neutralize anti-Fas or Fas-Ligand. Although we could not demonstrate a direct correlation between resistance of different hepatoma cell lines to Fas mediated death and endogenous expression of this transcript, we show that PLC/PRF 5 stable transfectants overexpressing Fas delta TM are less sensitive to anti-Fas than control cells. In three different cell lines, resistance to anti-Fas was overcome by treatment with the protein synthesis inhibitor cycloheximide. Although this could suggest the existence of short-lived repressors of the Fas-activated apoptotic signalling pathway(s), we show that translational inhibition is not required for the synergistic effect of cycloheximide to take place, and that resistant hepatoma cells can be sensitized to anti-Fas by subinhibitory concentrations of this protein synthesis inhibitor. Since cycloheximide is able to activate intracellular signalling independently on its effects on protein synthesis, we suggest that it might provide a costimulatory signal that cooperates with Fas in the induction of cell death and that, at least in the cells we tested, resistance to Fas is not an active process involving gene transcription and translation but only the consequence of an inadequate apoptotic stimulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7566976

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

1.  Involvement of PARP and poly(ADP-ribosyl)ation in the early stages of apoptosis and DNA replication.

Authors:  C M Simbulan-Rosenthal; D S Rosenthal; S Iyer; H Boulares; M E Smulson
Journal:  Mol Cell Biochem       Date:  1999-03       Impact factor: 3.396

2.  The hepatitis B virus X gene induces p53-mediated programmed cell death.

Authors:  P Chirillo; S Pagano; G Natoli; P L Puri; V L Burgio; C Balsano; M Levrero
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 3.  The Fas counterattack: a molecular mechanism of tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

4.  Apoptosis, angiogenesis, inflammation, and oxidative stress: basic interactions in patients with early and metastatic breast cancer.

Authors:  Enas A Hamed; Madeha M Zakhary; Doaa W Maximous
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-24       Impact factor: 4.553

5.  Prognostic value of serum soluble Fas in patients with locally advanced unresectable rectal cancer receiving concurrent chemoradiotherapy.

Authors:  Qi-lian Liang; Zhou-yu Li; Guo-qiang Chen; Zhen-nan Lai; Bi-rong Wang; Jie Huang
Journal:  J Zhejiang Univ Sci B       Date:  2010-12       Impact factor: 3.066

6.  Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma.

Authors:  M S Shin; W S Park; S Y Kim; H S Kim; S J Kang; K Y Song; J Y Park; S M Dong; J H Pi; R R Oh; J Y Lee; N J Yoo; S H Lee
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

7.  Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame.

Authors:  Weiliang Tang; Catherine A Lázaro; Jean S Campbell; W Tony Parks; Michael G Katze; Nelson Fausto
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

8.  Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system.

Authors:  Xiao-Zhong Wang; Xiao-Chun Chen; Yun-Xin Chen; Li-Juan Zhang; Dan Li; Feng-Lin Chen; Zhi-Xin Chen; Hong-Ying Chen; Qi-Ming Tao
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

9.  The distribution and intracellular location of Fas and Fas Ligand following gastric carcinogenesis: Fas Ligand expressing gastric carcinoma cells can inhibit local immune response.

Authors:  Huanran Liu; Hideyuki Ubukata; Takanobu Tabuchi; Takeshi Nakachi; Hiroyuki Nagata; Jiro Shimazaki; Gyou Motohashi; Satoru Konishi; Motoi Nishimura; Tetsuro Satani; JianWei Hong; Ichiro Nakada; Abbi R Saniabadi; Takafumi Tabuchi
Journal:  Mol Cell Biochem       Date:  2009-05-21       Impact factor: 3.396

10.  Inhibition of casein kinase 2 enhances the death ligand- and natural kiler cell-induced hepatocellular carcinoma cell death.

Authors:  H-R Kim; K Kim; K-H Lee; S J Kim; J Kim
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.